RxDoctor Payments Data

George Baxley, MD

Neurology · Clemson, SCNPI 1023009701

Payments from drug & device makers

$8,237in general payments, 2019–2025

Across 454 payments — averaging $18.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$1K
  • AbbVie$1K
  • Sanofi$454
  • Novartis$424
  • Amgen$348
  • Teva Pharmaceuticals USA, Inc.$325
  • plus $4K from 50 others

What the payments were for

  • Speaking & faculty fees$451%
  • Travel & lodging$1,21215%
  • Food & beverage$6,93384%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,237 in reported general payments places this provider in the 70th percentile of 270 neurology providers in South Carolina.

See all neurology providers in South Carolina

Medicare billing

Part B allowed, 2024
$274,217
Medicare patients
447
Services billed
13,104

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Avonex Pen (4 Pack)Interferon Beta-1a12$124,126
UbrelvyUbrogepant29$44,595
Nurtec OdtRimegepant Sulfate23$41,352
GlatopaGlatiramer Acetate12$32,256
Dimethyl Fumarate18$24,754
Aimovig AutoinjectorErenumab-Aooe23$20,888
ZavzpretZavegepant Hcl12$12,960
Dalfampridine ErDalfampridine21$12,540
TopamaxTopiramate11$11,240
Diclofenac Sodium55$4,883
LicartDiclofenac Epolamine12$4,475
Triazolam24$2,089
Carbidopa-LevodopaCarbidopa/Levodopa55$1,680
Duloxetine Hcl22$1,366
Carbamazepine ErCarbamazepine12$1,347

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerNurtec Odt, Zavzpret$160$54,31135 claims
AbbVieUbrelvy$1,170$44,59529 claims
Amneal Pharmaceuticals LLCPyridostigmine Bromide$11$83012 claims
Upsher-smith Laboratories LLCTopiramate$101$30340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 270 neurology providers in South Carolina.

Other neurology in Clemson

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →